NovoCure Limited - Ordinary Shares (NVCR) News
Filter NVCR News Items
NVCR News Results
|Loading, please wait...|
NVCR News Highlights
- NVCR's 30 day story count now stands at 4.
- Over the past 21 days, the trend for NVCR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CNS, ROOT and BASE are the most mentioned tickers in articles about NVCR.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
ROOT, Switzerland, September 21, 2022--Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocure’s U.S. CNS business, and is intended to renew focus on growth in Novocure’s glioblastoma (GBM) business.
NovoCure Ltd. is a commercial-stage oncology company that develops treatments for solid-tumor cancers. In this daily bar chart of NVCR, below, we can see that prices have traded sideways since December, building what I believe is a very impressive base. Prices have crisscrossed the 50-day moving average line for months and now NVCR is trading above this now bullish average line.
After losing 33% in the past year, NovoCure Limited (NASDAQ:NVCR) institutional owners must be relieved by the recent gain
If you want to know who really controls NovoCure Limited ( NASDAQ:NVCR ), then you'll have to look at the makeup of its...
ROOT, Switzerland, August 31, 2022--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation c
Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NASDAQ: NVCR) stock. Check out his reasoning in this video! *Stock prices used were the midday prices of Aug.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Ginkgo Bioworks (NYSE: DNA), and Novocure (NASDAQ: NVCR). Prosper Junior Bakiny (CRISPR Therapeutics): Despite tremendous medical progress in the past few decades, there is still plenty of work to do. Gene-editing leader CRISPR Therapeutics is one of them.
ROOT, Switzerland, August 10, 2022--On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s groundbreaking work to extend patient survival in some of the most aggressive forms of cancer.
Find out why these five Fool contributors like Novocure (NASDAQ: NVCR), The Trade Desk (NASDAQ: TTD), Walt Disney (NYSE: DIS), T-Mobile (NASDAQ: TMUS), and Rexford Industrial Realty (NYSE: REXR). Keith Speights (Novocure): Like many biotech stocks, Novocure has been beaten down a lot over the past 12 months. The company already markets its tumor treating fields (TTFields) therapy for treating glioblastoma, an aggressive type of brain cancer, and mesothelioma, a type of cancer caused by exposure to asbestos.
Good morning, everyone, and thank you for joining us to review NovoCure's second quarter 2022 performance. Other members of our executive leadership team are also on the call and available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, under quarterly report on our Investor Relations page.
NovoCure (NVCR) delivered earnings and revenue surprises of -64.29% and 4.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?